Recent news highlights Forian's financial performance and business developments, including significant revenue growth in Q2 2025 and ongoing earnings reports.

• Forian reported a 56 percent revenue increase in Q2 2025, reflecting strong growth in its information products business [N6][N7].
• The company was included in after-hours earnings reports in November 2025, indicating ongoing market and investor attention [N1].
• Forian's financial results and business activities have been regularly covered in Nasdaq articles alongside other technology and healthcare companies [N1].

Forian has demonstrated revenue growth driven by organic expansion and strategic acquisition of Kyber Data Science, enhancing its product suite and market reach. The company maintains strong liquidity and has reduced debt obligations, supporting operational flexibility. Increased adjusted EBITDA indicates improving operational efficiency. Continued investment in research and development and sales capabilities may support further product innovation and customer acquisition. The company's focus on healthcare and life sciences markets aligns with sectors that value data-driven insights for operational and financial optimization.

The company faces risks related to vendor contract terminations and the challenge of securing comparable data sources, which could impact product offerings and cost structures. Despite revenue growth, Forian reported net losses and negative earnings per share for fiscal 2025, indicating ongoing profitability challenges. The reduction in gross margin percentage suggests pressure on cost management. Legacy litigation claims, although reduced, represent potential liabilities. The company's reliance on acquisitions for growth introduces integration risks and potential operational complexities. Market concentration primarily in the U.S. may limit diversification.

Forian's moat is based on its proprietary data management capabilities and analytics solutions tailored to healthcare and life sciences sectors, which require specialized knowledge and compliance with regulatory standards. The company's integration of acquired entities like Kyber Data Science enhances its data assets and product offerings, potentially creating barriers to entry for competitors. Its established customer base primarily in the U.S. and ongoing investments in product development and sales infrastructure support its competitive positioning. However, reliance on third-party data vendors and the need to secure alternative data sources present operational challenges.

• Vendor Dependency and Data Licensing Risks: Forian relies on third-party data vendors for critical information products. Vendor contract terminations and business exits have led to adjustments and require the company to find alternative data sources, which may not be available on comparable terms.
• Profitability and Cost Pressure: Despite revenue growth, the company reported net losses and declining gross margins, reflecting increased costs from acquisitions and operations that may challenge profitability.
• Legacy Litigation Exposure: The company has incurred litigation settlements and related expenses from legacy claims assumed in prior mergers, which, although reduced recently, could pose financial and operational risks.
• Acquisition Integration Risks: Growth through acquisitions such as Kyber Data Science introduces risks related to integration, operational alignment, and realization of anticipated benefits.
• Market Concentration: The majority of sales are concentrated in the United States, which may expose the company to regional market risks and limit geographic diversification.

• Forian Inc. was incorporated in Delaware on October 15, 2020 as a wholly owned subsidiary of Forian LLC for the purpose of effecting a business combination with Helix Technologies, Inc.
• Forian provides data management capabilities and proprietary information and analytics solutions to optimize and measure operational, clinical, and financial performance for customers in healthcare, life sciences, and financial services industries.
• The company acquired Kyber Data Science, LLC on October 31, 2024, accounted for as a business combination with Forian as the accounting acquirer.
• Revenues are derived from fees for proprietary information products and services, recognized as performance obligations under customer contracts are satisfied.
• Geographically, sales are primarily in the United States (over 90%), with smaller portions in Great Britain, Australia, and Canada.
• Cost of revenues includes labor, information licensing, hosting, infrastructure, and client service team costs.
• The company experienced vendor contract terminations and changes affecting data licensing, with adjustments recorded in cost of revenues.
• Research and development expenses focus on adding new features and applications to product offerings.
• Sales and marketing expenses include salaries, commissions, advertising, market research, and events, with plans to expand selling and marketing staff.
• General and administrative expenses include salaries, benefits, professional fees, legal, accounting, and other corporate expenses.
• The company had litigation settlements and related expenses from legacy claims assumed in the Helix merger, which have decreased recently.
• Strategic review and acquisition related expenses relate to professional fees for an unsolicited offer to take the company private in 2025 and the Kyber acquisition in 2024.
• For the three months ended September 30, 2025, revenues were $7.76 million, up from $4.69 million in the same period in 2024, driven by the Kyber acquisition and organic growth.
• Cost of revenues for the same period increased to $3.75 million from $1.40 million, reducing gross margin percentage to 52% from 70%.
• Research and development expenses increased to $676,172 from $291,962 for the three months ended September 30, 2025 versus 2024, mainly due to the Kyber acquisition.
• Sales and marketing expenses increased to $1.46 million from $957,000 for the same period, reflecting acquisition impact and higher compensation.
• General and administrative expenses decreased to $2.12 million from $2.86 million, primarily due to lower stock compensation expense.
• Litigation settlements and related expenses were zero in the recent quarter, down from $1,394 previously.
• Interest and investment income decreased to $336,002 from $658,339, due to lower marketable securities balance after retiring convertible notes.
• Interest expense decreased to $35,984 from $195,415, reflecting redemption of convertible notes.
• For the nine months ended September 30, 2025, revenues were $22.29 million, up from $14.34 million in 2024, driven by acquisition and organic growth.
• Cost of revenues increased to $10.11 million from $4.91 million, reducing gross margin percentage to 55% from 66%.
• Adjusted EBITDA for the three months ended September 30, 2025 was $470,645, up from $185,916 in 2024, reflecting higher revenues partially offset by increased costs.
• Adjusted EBITDA for the nine months ended September 30, 2025 was $1,010,940, up from $368,535 in 2024.
• As of December 31, 2025, cash and cash equivalents were $12.9 million, short-term investments were $18.6 million, current assets totaled $42.6 million, and current liabilities were $14.4 million.
• Liquidity ratios as of December 31, 2025 included a current ratio of 2.97 and a cash ratio of 2.2, indicating strong short-term liquidity.
• Net income for the fiscal year ended December 31, 2025 was a loss of $2.87 million, with basic and diluted EPS of -$0.09 per share.
• The company has 31,240,882 shares outstanding as of April 27, 2026.
• The company has a board of directors with diverse expertise in healthcare, finance, and technology sectors.
• The company has been investing in expanding its sales and marketing capabilities and product development.
• The company has been managing vendor relationships and data licensing risks due to vendor business changes.
• The company has reduced litigation-related expenses significantly compared to prior periods.
• The company has redeemed convertible notes, reducing interest expense and debt obligations.
• The company funds operations through cash flow from operations, cash and marketable securities, debt financing, and equity issuances.